The article focuses on a partnership between pharmaceutical firm Sanofi and Mankind to market the drug Afrezza (Technosphere insulin) as of September 2013. The topics discussed include U.S. Food and Drug Administration (FDA)'s approval for Afrezza, requirement of four postmarketing trials for the drug, and the views of Christopher James, a senior biotech analyst, on the issue.